Get the latest Science News and Discoveries

Gilead’s anti-diversion clause for lenacapavir exploits vulnerable communities

Following the promising multicentre, international Purpose 1 and Purpose 2 clinical trials with lenacapavir for HIV prevention in vulnerable populations, Gilead’s anti-diversion clause to make the generic formula unavailable in certain middle income countries where trial participants live is more than what Yamey and Machingaidze call “a missed …

None

Get the Android app